



# ACTIVITY REPORT

2022

# ACTIVITY REPORT 2022





# TABLE OF CONTENTS

1. Presentation	5
2. Organisational Chart	9
3. Hospital Committees	11
<b>4. Healthcare Activity</b>	<b>19</b>
Assisted Patients	20
Pathology Distribution	21
Out-patient Consultations	25
Surgical Activity	30
Overall Activity Indicators	31
Central Services Activity	32
<b>5. Early Diagnosis Unit</b>	<b>37</b>
Marqués del Turia Early Diagnosis Unit II	38
I-ELCAP Early Detection Unit	39
Early Diagnosis of Prostate Cancer (Opportunistic Screening)	39





# PRESENTATION

1.



I am pleased to present the activities carried out at the Valencian Oncology Institute Foundation (IVO) throughout the year 2022. This work confirms the valuable contribution of the team that makes up this institution and, for yet another year, it has been driving the trajectory that the IVO has maintained for more than 45 years. It is defined by rigour, clinical excellence, and personalised care, focusing on the patient and their family.

In accordance with our mission, we have put all our efforts and resources once again at the service of Valencian society, caring for more than 30,000 patients.

Since it began its activity as a pioneering single-speciality centre in Spain, the IVO has consolidated its position as a national and international benchmark in the approach to cancer. As part of this process, the IVO received the Health Law Award in 2022, which acknowledges the institution's commitment to defending guarantees when it comes to the performance of healthcare professionals. For the third consecutive year, the hospital has also been distinguished with the World's Best Specialized Hospitals 2023, an award that places it among the best oncology hospitals in the world.

In addition to these distinctions, it is also privileged to have hosted one of the most important oncology meetings, which is held every year in Europe: the annual congress of the Organisation of European Cancer Institutes (OECl). This event has brought international recognition to the quality and excellence of the IVO's work, and has enabled it to project its endeavours throughout Europe.

These actions serve to recognise the exceptional team of professionals at IVO, who are committed to offering quality, personalised, and cutting-edge healthcare service. Through their knowledge, experience, and humanity, they are the ones who make this institution great.

Moreover, true to our commitment to continuous improvement, in 2022, we have made a great effort to upgrade our facilities and technological equipment in order to continue offering the best quality healthcare to our patients.

In this way, we have completed a cycle of technological renovation that has culminated with the incorporation of the two most advanced linear accelerators in the Valencian Community.

The Halcyon and VARIAN True-Beam models are the ultimate exemplars of state-of-the-art radiotherapy. This is a technological commitment aimed at successfully tackling any therapeutic procedure, no matter how complicated it may be, and at offering our patients quick treatment with the highest levels of precision and safety.



Alongside these milestones, in 2022:

- The IVO biobank was the first in Spain to obtain the international accreditation ISO20387—a standard that guarantees the quality management of biological material and accredits the technical competence of all the staff involved in the activity.
- The Medical Oncology Department has been re-accredited with the QOPI (Quality Oncology Practice Initiative) certification, an international benchmark programme that assesses quality in oncological care.

We face 2023 with the firm intention of persisting in the hard work of fighting cancer, maintaining our standards of quality, and the direct and humane treatment that distinguish this institution.

With the aim of highlighting the work carried out and to share the activity developed during the past 2022 year with you, we are disseminating this Healthcare and Scientific Report.

**Manuel Llombart Fuertes**  
**Director General de la Fundación IVO**






## ORGANISATIONAL CHART

2.







3.

## HOSPITAL COMMITTEES



## MANAGEMENT AND MONITORING COMMITTEE

	<b>NAME</b>	<b>POSITION</b>
President	Manuel Llombart Fuertes	General Management
Secretary	Belén Bolás Calduch	Communication Director
	Mº José Ortega García	Assistant Managing Director
	Tomás Quirós Morató	Medical Director
	Gonzalo Anaya Fernández-Albor	Chief Financial Officer - CFO
	Ignacio Galve Castillo	Information Systems Director
	Pedro Gómez Gómez	Human Resources Director
	Adela Lliso Sempere	Head Nurse
	Carlos J. Andrés Blasco	Head of Pharmacy Service
	Rodrigo Muñoz Balada	UDCA Head of Service
	Marcos Guaita Martínez	Head of the Clinical Analysis Service and Microbiology
	Ana Calatrava Fons	Head of the Anatomical Pathology Service
Spokespersons	Mª Ángeles Martínez Navarrete	Head of the Anaesthesia, Resuscitation, and Pain Therapy Service
	Rafael Estevan Estevan	Head of the General and Digestive Surgery Service
	Juan Carlos Peñalver Cuesta	Head of the Thoracic Surgery Service
	Onofre Sanmartín Jiménez	Head of the Dermatology Service
	Oscar Cruz Piñero Sánchez	Head of the Gynaecology Service
	Ignacio Gil-Bazo	Head of the Medical Oncology Service
	Leoncio Arribas Alpuente	Head of the Radiation Oncology Service
	Juan Bosco Vendrell Marqués	Head of the Ear, Nose and Throat Service
	José Cervera Deval	Head of the Radiology Service
	Vicente Enrique Miró Palau	Clinical Head of Cardiology
	Vicente Crispín Contreras	Radiophysics and Radiological Protection Service

Antonio Mancheño Álvaro	Home Hospitalisation Unit Coordinator
Rafael Díaz Expósito	Head of the Nuclear Medicine Service
Francisco José Pascual Plá	Emergency Unit Coordinator
Carmen Martínez Lapiedra	Clinical Head of the Digestive Unit
Adoración Egido González	Clinical Head of the Internal Medicine Unit
Nuria Nácher Alonso	Clinical Head of the Early Diagnosis Unit
José Antonio López Guerrero	Head of the Molecular Biology Service
Elisa Bañuls Sendra	Physiotherapy Service
Rocío Romero Retes	Psycho-Oncology Unit Psychologist
Javier García Latorre	Head Orderly
Ana Pérez Balaguer, Eduardo Ferrandis Perepérez, Mª Dolores Solís Moreno y Amparo Devís Gamar	Employees' Council

## TRANSFUSION COMMITTEE

	NAME	POSITION
President	Claudia Juliana Salazar Lozada	Transfusion Service Manager
	Amparo Avaria Navalón	Haematology Unit Assistant Physician
	Adela Lliso Sempere	Head Nurse
Spokespersons	Francisco José Pascual Plá	UDCA Assistant Physician
	Juan Carlos Peñalver Cuesta	Head of Thoracic Surgery Service
	Mª Ángeles Martínez Navarrete	Head of Anaesthesia, Resuscitation, and Pain Therapy
	Tomás Quirós Morató	Medical Director
	Josefa Samper Hiraldo	Emergency Unit Assistant Physician

## EQUALITY COMMISSION

	<b>NAME</b>	<b>POSITION</b>
Workers' Representation	Amparo Devís Gamir	CC.OO.
	María Dolores Solís Moreno	CSIF
	Rosario Valero Valero	CC.OO.
Company Representation	Mª José Ortega García	Assistant Managing Director
	Pedro Antonio Gómez Gómez	Human Resources Director

## ETHICS COMMITTEE ON RESEARCH INVOLVING MEDICINAL PRODUCTS

	<b>NAME</b>	<b>POSITION</b>
President	Esteban Morcillo Sánchez	Clinical Pharmacologist
Technical Secretary	Carlos J. Andrés Blasco	Pharmacist Specialising in Hospital Pharmacy
	Ignacio Gil- Bazo	Physician Specialising in Medical Oncology
	Ismael Pastor Climente	Pharmacist Specialising in Hospital Pharmacy
	Joaquín Gavilá Gregori	Specialist in Medical Oncology
	Ángel Luis Guerrero Zotano	Specialist in Medical Oncology
	Lourdes Bello Luna	Graduate in Law
	María José Ortega García	Graduate in Law
	Esteban Mesas Plaza	Degree in Nursing
	Elena Oliete Ramírez	Physician Specialising in Family and Community Medicine
	Julio Tudela Cuenca	Pharmacist Specialising in Clinical Analysis
	José Luis Trillo	Primary Healthcare Pharmacist
	Luis Gómez de Membrillera Quesada	Physician Specialising in Family and Community Medicine
	David Hervás Marín	Degree in Biostatistics
	Josefina Balaguer Cusí	Non-professional Member
	Javier González Cervantes	Diploma in Nursing
	Antonio José Revert Ventura	Physician Specialising in Radiology
	Miguel Ángel Sanz Alonso	Physician Specialising in Haematology

## BIOBANK

NAME	POSITION
Manuel Llombart Fuertes	General Management
Isabel Gil Aldea	Scientific Director of the Biobank
Ana Calatrava Fons	Head of Anatomical Pathology Service
José Antonio López	Head of Molecular Biology Service
Nuria López Pérez-Madero	Documentary Technician
María Isabel Cortell Granero	Technician Specialising in Molecular Biology

## HEALTH AND SAFETY COMMITTEE

	NAME	POSITION
Company Representatives	Tomás Quirós Morató	Medical Director
	Maria José Ortega García	Assistant Managing Director
	Álvaro Minguet Calas	Engineer
	Vicente Crispín Contreras	Radiophysics and Radiological Protection Service
Prevention Delegates	Josefina Larrosa	Nurse
	Lucas Valero Corraliza	Pathological Anatomy Technician
	María Cruz Navarro López	Anatomical Pathology Technique
	Amparo Devís Gamir	Administrative Officer

## TEACHING COMMITTEE

	NAME	POSITION
President	Onofre Sanmartín Jiménez	Head of Dermatology Service
Secretary	Lourdes Bello Luna	Graduate in Law
Vocales	Marcos Melian Sosa	Tutor and Assistant Medical Oncology Physician
	Sergio Sandiego Contreras	Tutor and Assistant Medical Oncology Physician
	Mª Luisa Chust Climent	Tutor and Head of the Radiation Oncology Clinic
	Carlos Serra Guillén	Dermatology Tutor and Assistant Physician
	Vicente Crispín Contreras	Radiophysics and Radiological Protection Service
	Carlos J. Andrés Blasco	Head of Pharmacy Service
	Pilar Ferrer Peñaranda	ConSELLERÍA de Sanidad Representative
	Lucia Morales López	Representative of the Specialists in Training
	Carlos Fuster Diana	Clinical Head of the General and Digestive Surgery Service

## COMMITTEE ON PHARMACOTHERAPY IN HEALTHCARE AND CLINICAL TRIALS

	<b>NAME</b>	<b>POSITION</b>
President	Carlos J. Andrés Blasco	Pharmacist Specialising in Hospital Pharmacy
Spokespersons	Ismael Pastor Climente	Pharmacist Specialising in Hospital Pharmacy. Representative of the hospital's management.
	Ignacio Gil-Bazo	Specialist in Medical Oncology
	Sergio Sandiego Contreras	Specialist in Medical Oncology
	Elena Oliete Ramírez	Specialist in Family and Community Medicine
	Lourdes Bello Luna	Graduate in Law
	Belén Vázquez Blanco	Degree in Nursing. Coordinator of the IVO Foundation's Research Unit.
	Bernat Navarro Aguir	Degree in Pharmacy. Coordinator of the IVO Foundation's Technical Secretariat of the CEIM
	Beatrix Llatas Serrano	Administration of the IVO Foundation's Technical Secretariat of the CEIM

## INFECTION AND PROPHYLAXIS COMMISSION

	<b>NAME</b>	<b>POSITION</b>
Presidente	Tomás Quirós Morató	Medical Director
Vocales	Marcos Guaita Martínez	Head of the Clinical Analysis and Microbiology Laboratory Service
	Tomás García Lozano	Assistant Physician of the Clinical Analysis and Microbiology Laboratory Service
	Adoración Egido González	Clinical Head of Internal Medicine
	Javier Ortega Giménez	Assistant Physician of Anaesthesiology
	Francisco José Pascual Plá	UDCA Assistant Physician
	Yolanda Colomer Nieves	Pharmacist
	Adela Lliso Sempere	Head Nurse
	Carmen Juárez Martí	Surgical Services Supervisor

## QUALITY AND ENVIRONMENTAL MANAGEMENT COMMITTEE

	<b>NAME</b>	<b>POSITION</b>
President	Tomás Quirós Morató	Medical Director
Secretary	Catalina Trenor Escuin	Quality Department
	Marcos Guaita Martínez	Head of Clinical Analysis and Microbiology Laboratory Service
	Vicente Moya Sahorí	UDCA Assistant Physician
	Francisco José Pascual Plá	UDCA Assistant Physician
	Marina Sánchez Yepes	Assistant Physician of the Clinical Analysis and Microbiology Laboratory Service
	Leoncio Arribas Alpuente	Head of Radiation Oncology Service
	Manuel Casaña Giron	Assistant Physician of the Radiation Oncology Department
	Vicente Crispín Contreras	Head of the Radiophysics and Radiological Protection Service
Spokespersons	Claudia Juliana Salazar Lozada	Assistant Physician of the Haematology Unit
	Rafael Díaz Expósito	Head of Nuclear Medicine Service
	Marina Costa Moreno	Nuclear Medicine Service Nurse
	Ana Calatrava Fons	Head of Anatomical Pathology Service
	Alvaro Minguet Calas	Engineer
	Pedro Gómez Gómez	Human Resources Director
	María Isabel Cortell Granero	Specialist Technician in Molecular Biology
	Adela Lliso Sempere	Head Nurse
	Amparo Quilis Gimeno	Radiation Oncology Nurse Supervisor
	José Julio Ferrando Pastor	Assistant Physician of the Emergency Unit

## MEDICAL RECORDS COMMISSION

	<b>NAME</b>	<b>POSITION</b>
President	Francisco José Pascual Plá	UDCA Assistant Physician
Secretary	Catalina Trenor Escuin	Quality Department
	Tomás Quirós Morató	Medical Director
	Vicente Moyá Sahorí	UDCA Assistant Physician
	Adela Lliso Sempere	Head Nurse
	Julia Pardo Seré	Emergency Unit Associate Doctor
	Celia López de Briñas Monfort	Clinical Head of ARPT
	Giovanni Vento	Assistant Physician of the General and Digestive Surgery Service
Spokespersons	José Cervera Deval	Head of Radiology Service
	Raimundo Novella Cañadas	Information Systems
	Enrique García Miragall	Clinical Head of the Radiation Oncology Service
	Joaquín Gavilá Gregorí	Clinical Head of the Medical Oncology Service
	Antonio Mancheño Álvaro	Home Hospitalisation Unit Coordinator
	Mª José Castro Boix	Documentary Technician
	Vicente Crispín Contreras	Head of the Radiophysics Service
	Rodrigo Muñoz Balada	Head of the UDCA

## EMPLOYEES' COUNCIL

<b>NAME</b>	<b>POSITION</b>
Amparo Devís Gamir	Administrative Officer
Juana Escribá Fornes	Nurse
María Cruz Navarro López	Anatomical Pathology Technique
Ana Ferrer Rafael	Radiodiagnostic Technique
Ana Pérez Balaguer	Administrative Officer
Rosario Valero Valero	Technician Specialising in Radiotherapy
Amparo Alcina Núñez	Nursing Assistant
Mª José Talaya Ballester	Nursing Assistant
Isabel Catalá Navarro	Administrative Officer
Eduardo Ferrandis Pérez	Clinical Head of Ear, Nose and Throat
Maria Dolores Solís Moreno	Nursing Assistant
Yolanda Pinar Montiel	Clinical Assistant
Josefina Larrosa Moya	Nurse
María Ángeles Mayordomo Sánchez	Nurse
Lucas Valero Corraliza	Anatomical Pathology Laboratory Technician
Juan Andrés Calvet Sánchez	IT Engineer
Lucrecia Sanjuan Reche	Nurse



## HEALTHCARE REPORT

4.

# CANCER CARE


## NUMBER OF PATIENTS ASSISTED

	2022	2021	Dif.	% Desv
New Patients	6.706	6.037	669	11%
Prevalent Patients	23.839	22.498	1.341	6%
<b>TOTAL</b>	<b>30.545</b>	<b>28.535</b>	<b>2.010</b>	<b>7%</b>

## NEW PATIENTS ORIGIN


	2022	2021	Dif.	% Desv
ALICANTE	902	1.035	-133	-13%
CASTELLÓN	296	141	155	110%
VALENCIA	4.998	4.421	577	13%
OTHER AUTONOMOUS COMMUNITIES	315	350	-35	10%
OTHER ENTITIES	195	90	105	117%
<b>TOTAL</b>	<b>6.706</b>	<b>6.037</b>	<b>669</b>	<b>11%</b>

## NEW PATIENTS




# PATHOLOGY DISTRIBUTION

## DISTRIBUTION OF PATHOLOGY



## MALIGNANT PATHOLOGY EVOLUTION (1978-2022)



## MALIGNANT PATHOLOGY BY TOPOGRAPHY

	2022	2021	Dif.	% Dsv
<b>MALIGNANT TUMOURS OF THE HEAD AND NECK</b>				
C00 - LIP	10	3	7	233%
C01 - C02 - TONGUE	32	34	-2	-6%
C03 - GUM	9	1	8	800%
C04 - C05 - MOUTH	6	5	1	20%
C06 - OTHER PARTS OF THE MOUTH	10	21	-11	-52%
C07 - C08 - SALIVARY GLANDS	37	14	23	164%
C09 - C10 - TONSIL - OROPHARYNX	61	30	31	103%
C11 - NASOPHARYNX	16	9	7	78%
C12 - C13 - HYPOPHARYNX	24	23	1	4%
<b>SUBTOTAL</b>	<b>205</b>	<b>140</b>	<b>65</b>	<b>46%</b>
<b>MALIGNANT TUMOURS OF THE DIGESTIVE SYSTEM</b>				
C15 - OESOPHAGUS	52	47	5	11%
C16 - STOMACH	62	30	32	107%
C17 - SMALL INTESTINE	3	4	-1	-25%
C18 - LARGE INTESTINE	208	163	45	28%
C19 - C21 - RECTUM - RECTOSIGMOID JUNCTION	156	135	21	16%
C22 - LIVER AND INTRAHEPATIC BILE DUCTS	31	34	-3	-9%
C23 - C24 - GALLBLADDER AND EXTRAHEPATIC BILE DUCTS	9	9	0	0%
C25 - PANCREAS	86	66	20	30%
<b>SUBTOTAL</b>	<b>607</b>	<b>488</b>	<b>119</b>	<b>24%</b>
<b>MALIGNANT TUMOURS OF THE RESPIRATORY SYSTEM</b>				
C30 - C31 - NOSE, NOSTRILS, MIDDLE EAR, AND SINUSES	14	3	11	367%
C32 - LARYNX	116	87	29	33%
C34 - TRACHEA, BRONCHI, AND LUNG	601	475	126	27%
C38 - PLEURA	0	9	-9	-100%
C37 - THYMUS AND MEDIASTINUM	7	4	3	75%
<b>SUBTOTAL</b>	<b>738</b>	<b>578</b>	<b>160</b>	<b>28%</b>
<b>BONE SARCOMAS</b>				
C40 - C41 - BONE	3	19	-16	-84%
<b>SUBTOTAL</b>	<b>3</b>	<b>55</b>	<b>-52</b>	<b>-95%</b>
<b>SKIN AND MELANOMAS</b>				

C43 - MELANOMA	196	158	38	24%
C44 - SKIN	581	705	-124	-18%
<b>SUBTOTAL</b>	<b>777</b>	<b>863</b>	<b>-86</b>	<b>-10%</b>
BREAST				
C50 - BREAST	1.189	657	532	81%
<b>SUBTOTAL</b>	<b>1.189</b>	<b>657</b>	<b>532</b>	<b>81%</b>
<b>SOFT-TISSUE SARCOMA</b>				
C4A - MERKEL CELL CARCINOMA	3	0	3	300%
C45 - MESOTHELIOMA	3	3	0	0%
C46 - KAPOSI SARCOMA	1	1	0	0%
C48 - PERITONEUM AND RETROPERITONEUM	1	12	-11	-92%
C49 - CONNECTIVE TISSUE	4	36	-32	-89%
<b>SUBTOTAL</b>	<b>12</b>	<b>52</b>	<b>-40</b>	<b>-77%</b>
<b>FEMALE GENITAL SYSTEM</b>				
C51 - C52 - VULVA AND VAGINA	27	17	10	59%
C53 - CERVIX UTERI	57	55	2	4%
C54 - CORPUS UTERI	84	83	1	1%
C55 - UTERUS, PART UNSPECIFIED	11	15	-4	-27%
C56-C57 - OVARY AND TUBE	41	32	9	28%
<b>SUBTOTAL</b>	<b>220</b>	<b>202</b>	<b>18</b>	<b>9%</b>
<b>MALE URINARY AND GENITAL SYSTEM</b>				
C60 - PENIS	10	19	-9	-47%
C61 - PROSTATE	805	609	196	32%
C62 - TESTICLE	24	11	13	118%
C67 - BLADDER	270	267	3	1%
C64 - KIDNEY	118	66	52	79%
<b>SUBTOTAL</b>	<b>1227</b>	<b>972</b>	<b>255</b>	<b>26%</b>
<b>NERVOUS SYSTEM AND ENDOCRINE GLANDS</b>				
C69 - EYE	0	1	-1	-100%
C70 - MENINGES	7	6	1	17%
C71 - BRAIN	30	46	-16	-35%
C73 - THYROIDS	22	29	-7	-24%
C74 - C75 - OTHER ENDOCRINE GLANDS	5	11	-6	-55%
<b>SUBTOTAL</b>	<b>64</b>	<b>93</b>	<b>-29</b>	<b>-31%</b>
<b>METASTASIS OF UNKNOWN ORIGIN</b>				


C76 - OTHER SITES AND ILL-DEFINED SITES	6	9	-3	-33%
C77 - GLANGLIONIC METASTASES OF U. O.	6	9	-3	-33%
C78 - RESPIRATORY AND DIGESTIVE M+ OF U. O.	34	22	12	55%
C79 - OTHER METASTASES OF U. ORIGIN	52	86	-34	-40%
C80 - METASTASIS OF UNSPECIFIED SITE	28	8	20	250%
<b>SUBTOTAL</b>	<b>126</b>	<b>134</b>	<b>-8</b>	<b>-6%</b>
<b>HAEMOPOIETIC ORGANS</b>				
C81 - HODGKIN	7	5	2	40%
C82-C84/C86-C88 - OTHER LYMPHOMATOUS TUMOURS	40	32	8	25%
C85 - NON-HODGKIN'S LYMPHOMA	6	16	-10	-63%
C90 - MYELOMA	12	14	-2	-14%
C91 - LYMPHOID LEUKAEMIA	2	3	-1	-33%
C92 - MYELOID LEUKAEMIA	2	2	0	0%
C95 - LEUKAEMIA OF UNSPECIFIED CELL TYPE	0	2	-2	-100%
<b>SUBTOTAL</b>	<b>69</b>	<b>74</b>	<b>-5</b>	<b>.7%</b>
<b>BENIGN NEOPLASM OF THE BRAIN AND OTHER PARTS OF THE CNS</b>				
D3A - NEUROENDOCRINE TUMOURS	0	3	-3	-100%
D33 - BENIGN NEOPLASM OF BRAIN	12	11	1	9%
<b>SUBTOTAL</b>	<b>12</b>	<b>14</b>	<b>2</b>	<b>-14%</b>
<b>CARCINOMA IN SITU</b>				
D01 - DIGESTIVE ORGANS	68	3	65	2167%
D02 - RESPIRATORY SYSTEM	68	5	63	1260%
D04 - SKIN	17	10	7	70%
D05-D09 - BREAST AND GENITOURINARY SYSTEM	22	51	-29	-57%
D09.19 - CARCINOMA IN SITU OF OTHER SITES	0	0	0	0%
<b>SUBTOTAL</b>	<b>175</b>	<b>69</b>	<b>106</b>	<b>154%</b>
<b>TUMOUR WITH UNCERTAIN EVOLUTION</b>				
D37. D38.6 - DIGESTIVE AND RESPIRATORY SYSTEMS	281	296	-15	-5%
D39- D40-D41 - GENITOURINARY ORGANS	433	543	-110	-20%
D44 - NEOPLASM OF UNDETERMINED BEHAVIOUR OF ENDOCRINE GLANDS	46	38	8	21%
D48 - NEOPLASM OF UNDETERMINED OR UNKNOWN BEHAVIOUR	253	247	6	2%
D49 - UNDETERMINED NATURE	0	300	-300	-100%
<b>SUBTOTAL</b>	<b>1013</b>	<b>1.424</b>	<b>-411</b>	<b>-29%</b>
<b>TOTAL MALIGNANT PATHOLOGY</b>	<b>6.437</b>	<b>5.779</b>	<b>658</b>	<b>11%</b>

# OUTPATIENT ACTIVITY

## OUTPATIENT ACTIVITY

	2022			2021			Dif.	% Desv.
	First Visits	Successive Visits	Total	First Visits	Successive Visits	Total		
Anaesthesia and Resuscitation	3.292	1.221	<b>4.513</b>	3.124	1.297	<b>4.421</b>	92	2%
Cardiology	420	748	<b>1.168</b>	422	658	<b>1.080</b>	88	8%
Digestive Surgery	360	2.117	<b>2.477</b>	444	2.399	<b>2.843</b>	-366	-13%
Breast Surgery	622	5.117	<b>5.739</b>	494	4.693	<b>5.187</b>	552	11%
General Surgery	25	16	<b>41</b>	24	25	<b>49</b>	-8	-16%
Plastic Surgery	82	651	<b>733</b>	74	533	<b>607</b>	126	21%
Thoracic Surgery	195	993	<b>1.188</b>	223	1.145	<b>1.368</b>	-180	-13%
Genetic Counselling	279	193	<b>472</b>	230	187	<b>417</b>	55	13%
Orthopaedic Surgery and Traumatology	171	486	<b>657</b>	207	618	<b>825</b>	-168	-20%
Dermatology	812	9.716	<b>10.528</b>	693	9.761	<b>10.454</b>	74	1%
Gastrointestinal Tract	337	3.098	<b>3.435</b>	274	3.389	<b>3.663</b>	-228	-6%
Lymphatic Drainage	7	1.798	<b>1.805</b>	5	2.142	<b>2.147</b>	-342	-16%
Physiotherapy	77	1.834	<b>1.911</b>	73	1.774	<b>1.847</b>	64	3%
Gynaecology	407	5.959	<b>6.366</b>	316	5.821	<b>6.137</b>	229	4%
Haematology	218	2.746	<b>2.964</b>	233	2.917	<b>3.150</b>	-186	-6%
Internal Medicine	161	1.320	<b>1.481</b>	146	1.303	<b>1.449</b>	32	2%
Nuclear Medicine	9	95	<b>104</b>	26	119	<b>145</b>	-41	-28%
Pneumology	172	688	<b>860</b>	187	671	<b>858</b>	2	0%
Neurosurgery	17	67	<b>84</b>	13	64	<b>77</b>	7	9%
Neurology	20	369	<b>389</b>	16	407	<b>423</b>	-34	-8%
Nutrition	123	446	<b>569</b>	148	421	<b>569</b>	0	0%
Medical Oncology	1.409	34.015	<b>35.424</b>	1.228	33.392	<b>34.620</b>	804	2%
Radiation Oncology	3.139	13.439	<b>16.578</b>	2.910	13.446	<b>16.356</b>	222	1%
Ear, Nose and Throat	343	4.365	<b>4.708</b>	267	4.207	<b>4.474</b>	234	5%
Psycho-Oncology	300	1.888	<b>2.188</b>	244	2.059	<b>2.303</b>	-115	-5%
Pain Therapeutics	76	219	<b>295</b>	71	191	<b>262</b>	33	13%
Urology	1.147	14.962	<b>16.109</b>	1.006	15.626	<b>16.632</b>	-523	-3%
<b>Totals</b>	<b>14.220</b>	<b>108.566</b>	<b>122.786</b>	<b>13.098</b>	<b>109.265</b>	<b>122.363</b>	<b>423</b>	<b>0%</b>

## OUTPATIENT CONSULTATIONS




# DAY HOSPITAL ACTIVITY

## DAY HOSPITAL

	2022	2021	Dif.	% Desv.
Medical Oncology	17.969	16.505	1.464	9%
Haematology	549	457	92	20%
Urology	1.739	1.641	98	6%
<b>TOTAL</b>	<b>20.257</b>	<b>18.603</b>	<b>1.654</b>	<b>9%</b>

## DAY HOSPITAL



# ACTIVITY IN THE EMERGENCY DEPARTMENT

## ACTIVITY INDICATORS


	2022	2021	Dif.	% Desv.
Number of emergencies	6.505	6.074	431	7%
Urgent hospitalisations	1.549	1.658	-109	-7%

## HOSPITAL STAYS

	2022	2021	Dif.	% Desv.
ARPT	343	137	206	150%
GENERAL AND DIGESTIVE TRACT SURGERY	2.496	3.134	-638	-20%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	34	66	-32	-48%
THORACIC SURGERY	541	667	-126	-19%
DERMATOLOGY	6	6	0	0%
DIGESTIVE	44	49	-5	-10%
GYNAECOLOGY	801	636	165	26%
HAEMATOLOGY	428	269	159	59%
INTERNAL MEDICINE	3.027	2.853	174	6%
NUCLEAR MEDICINE	46	49	-3	-6%
MEDICAL ONCOLOGY	8.296	7.232	1.064	15%
EAR, NOSE AND THROAT	1.540	1.422	118	8%
RADIATION THERAPY	950	1.455	-505	-35%
UROLOGY	3.898	4.195	-297	-7%
INTENSIVE CARE UNIT	2.677	2.929	-252	-9%
<b>HOSPITAL TOTAL</b>	<b>25.127</b>	<b>25.099</b>	<b>28</b>	<b>0%</b>
HOME HOSPITALISATION UNIT	25.667	27.137	-1470	-5%

## NUMBER OF DISCHARGES


	2022	2021	Dif.	% Desv.
ARPT	51	43	8	19%
GENERAL AND GASTROINTESTINAL TRACT SURGERY	1.240	1.251	-11	-1%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	18	16	2	13%
THORACIC SURGERY	216	265	-49	-18%
DERMATOLOGY	4	9	-5	-56%
DIGESTIVE	31	47	-16	-34%
GYNAECOLOGY	338	329	9	3%
HAEMATOLOGY	54	42	12	29%
INTERNAL MEDICINE	425	449	-24	-5%
NUCLEAR MEDICINE	39	28	11	39%
MEDICAL ONCOLOGY	1.038	1.019	19	2%
EAR, NOSE AND THROAT	316	316	0	0%
RADIATION THERAPY	262	353	-91	-26%
UROLOGY	1.487	1.566	-79	-5%
INTENSIVE CARE UNIT	1.332	1.427	-95	-7%
<b>HOSPITAL TOTAL</b>	<b>6.851</b>	<b>7.160</b>	<b>-309</b>	<b>-4%</b>
HOME HOSPITALISATION UNIT	510	535	-25	-5%



# SURGICAL ACTIVITY

## NUMBER OF PATIENTS OPERATED ON

	2022	2021	Dif.	% Desv.
GENERAL AND GASTROINTESTINAL TRACT SURGERY	1.169	1.172	-3	0%
PLASTIC SURGERY	120	65	55	85%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	18	21	-3	-14%
THORACIC SURGERY	148	175	-27	-15%
DERMATOLOGY	970	671	299	45%
GYNAECOLOGY	323	304	19	6%
EAR, NOSE AND THROAT	307	311	-4	-1%
ANAESTHESIA AND RESUSCITATION	67	77	-10	-13%
RADIOOTHERAPY - BRACHYTHERAPY	234	299	-65	-22%
UROLOGY	1.365	1.421	-56	-4%
<b>TOTAL</b>	<b>4.402</b>	<b>4.516</b>	<b>-114</b>	<b>-3%</b>
ROBOTIC SURGERY	239	95	144	152%



# OVERALL ACTIVITY INDICATORS

## OVERALL HOSPITAL INDICATORS

	2022	2021	Dif.	% Desv.
Occupancy Rate	76,54%	72,6%	3,94%	5%
Turnover Rate	89,74%	68,6	21,14%	31%
Average Stay	3,7	3,5	0,2	6%

## AVERAGE STAY PER SERVICE

	2022	2021	Dif.	% Desv.
ARPT	6,7	3,2	3,5	109%
GENERAL AND GASTROINTESTINAL TRACT SURGERY	2,0	2,5	-0,5	-20%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	1,9	4,1	-2,2	-54%
THORACIC SURGERY	2,5	2,5	0	0%
DERMATOLOGY	1,5	0,7	0,8	114%
DIGESTIVE	1,4	1,0	0,4	40%
GYNAECOLOGY	2,4	1,9	0,5	26%
HAEMATOLOGY	7,9	6,4	1,5	23%
INTERNAL MEDICINE	7,1	6,4	0,7	11%
NUCLEAR MEDICINE	1,2	1,8	-0,6	-33%
MEDICAL ONCOLOGY	8,0	7,1	0,9	13%
EAR, NOSE AND THROAT	4,9	4,5	0,4	9%
RADIATION THERAPY	3,6	4,1	-0,5	-12%
UROLOGY	2,6	2,7	-0,1	-4%
INTENSIVE CARE UNIT	2,0	2,1	-0,1	-5%
<b>HOSPITAL TOTAL</b>	<b>3,7</b>	<b>3,5</b>	<b>0,2</b>	<b>6%</b>
HOME HOSPITALISATION UNIT	50,3	50,7	-0,4	-1%

# CLINICAL ANALYSIS AND MICROBIOLOGY LABORATORY

## ACTIVITY INDICATORS

		2022	2021	Dif.	% Desv.
BIOCHEMISTRY	Petitions	70.018	70.072	-54	-0,1%
	Determinations	2.636.935	2.595.906	41.029	2%
MICROBIOLOGY	Bacteriology	41.547	29.963	11.584	39%
	Serology	3.867	5.328	-1.461	-27%
HEMATIMETRY	Petitions	57.977	57.641	336	0,6%
	Determinations	1.217.517	1.210.461	7.056	0,6%
HAEMOSTASIS	Petitions	18.832	19.638	-806	-4%
	Determinations	75.328	78.552	-3.224	-4%
BLOOD BANK	Red blood cells	1.806	1.707	99	6%
	Plasma	46	62	-16	-26%
	Platelets	151	102	49	48%
TUMOUR MARKERS		41.074	41.779	-705	-2%
IMMUNOLOGICAL STUDIES		48.118	44.982	3.136	7%

# PATHOLOGICAL ANATOMY

## BIOPSIES

	2022	2021	Dif.	% Desv.
Number of Patients	8.222	8.530	-308	-4%
Number of Biopsies	28.546	27.611	935	3%

## CERVICAL SCREENING

	2022	2021	Dif.	% Desv.
I.V.O.	Vaginal	1.393	1.682	-289
	Non-vaginal	1.697	1.478	219
Early Diagnosis Unit	3.449	3.289	160	5%
<b>TOTAL</b>	<b>6.539</b>	<b>6.449</b>	<b>90</b>	<b>1%</b>

## IMMUNOHISTOCHEMISTRY

	2022	2021	Dif.	% Desv.
Number	15.974	16.685	-711	-4%

## SILVER-ENHANCED IN SITU HYBRIDISATION (SISH)

	2022	2021	Dif.	% Desv.
Number	87	72	15	21%

## OSNA (One-Step Nucleic Acid Amplification)

	2022	2021	Dif.	% Desv.
Number	646	616	30	5%

## AUTOPSIES

	2022	2021	Dif.	% Desv.
Number of Autopsies	1	1	0	0%

# MOLECULAR BIOLOGY

## NUMBER OF SAMPLES ANALYSED PER PROCESS

ANALYSIS TYPE	2022	2021	Dif.	% Desv.
COVID-19	4.384	4.176	208	5%
BCR-ABL QUANTITATIVE DETERMINATION	25	32	-7	-22%
MICROSATELLITE INSTABILITY STUDY (MSI)	133	171	-38	-22%
RNA EXTRACTION	4.440	4.223	217	5%
DNA EXTRACTION	1.475	1.546	-71	-5%
CELL-FREE DNA EXTRACTION	132	187	-55	-29%
FISH (Fluorescence In Situ Hybridization)	851	884	-33	-4%
FACTOR II (PROTOMBIN)	2	0	2	-
FACTOR V LEIDEN	2	0	2	-
HPV FRAGMENTS	27	24	3	13%
HAEMOCHROMATOSIS	2	6	-4	-67%
HYPERMETHYLATION OF THE MLH1 GENE PROMOTER	42	26	20	77%
MLPA (BRCA1, BRCA2, CKEK2)	12	3	9	300%
JAK2 QUALITATIVE PCR	19	13	6	46%
QUANT. PCR (EGFR, BRAF, K.-RAS, N-RAS, PI3KCA)	547	725	-178	-25%
QUALITATIVE PCR POLYOMAVIRUS	7	0	7	-
HCS PANEL (70 Genes)	285	210	75	36%
HRS PANEL (16 Genes)	59	57	2	4%
STS PANEL (42 Genes)	398	468	-70	-15%
DPYD POLYMORPHISMS	94	94	0	-
IGH REARRANGEMENTS	41	28	13	46%
TCR REARRANGEMENTS	75	25	50	200%
SANGER SEQUENCING	268	276	-8	-3%
<b>TOTAL DETERMINATIONS</b>	<b>13.320</b>	<b>13.174</b>	<b>146</b>	<b>1%</b>

# NUCLEAR MEDICINE

## ACTIVITY INDICATORS

	2022	2021	Dif.	% Desv.
VENTRICULAR EJECTION FRACTION	12	10	2	20%
SENTINEL GANGLION	405	370	35	9%
BONE SCANNING	1.176	1.102	74	7%
OTHER	25	39	-14	-36%
SPECT	135	183	-48	-26%
PET	2.081	1.791	290	16%
<b>GRAND TOTAL</b>	<b>3.834</b>	<b>3.495</b>	<b>339</b>	<b>10%</b>

## METABOLIC THERAPY

	2022	2021	Dif.	% Desv.
Discharges	39	28	11	39%
Stays	46	49	-3	-6%
Average Stay	1,2	1,8	-0,6	-33%

# RADIOLOGY

## ACTIVITY INDICATORS

	2022	2021	Dif.	% Desv.
CT Scan	23.776	26.533	-2.757	-10%
MRI	4.165	4.033	132	3%
ULTRASOUNDS	10.016	8.265	1.751	21%
DOPPLER	251	274	-23	-8%
MAMMOGRAMS	5.596	5.528	68	1%
PLAIN AND CONTRAST-ENHANCED RADIOLOGY	7.257	7.181	76	1%
INTERVENTIONAL RADIOLOGY	3.403	3.034	369	12%
RADIOSCOPY OPERATING ROOM	209	246	-37	-15%
DENSITOMETRY	2.488	2.424	64	3%
<b>GRAND TOTAL</b>	<b>57.161</b>	<b>57.518</b>	<b>-357</b>	<b>-1%</b>

# RADIATION ONCOLOGY

## RADIOSURGERY TREATMENTS

	2022	2021	Dif.	% Desv.
External Radiation Therapy	366	599	-233	-39%
Special Techniques	2.323	1.935	388	20%
Brachytherapy	247	316	-69	-22%
Radiosurgery	42	63	-21	-33%
<b>GRAND TOTAL</b>	<b>2.978</b>	<b>2.913</b>	<b>65</b>	<b>2%</b>



## EARLY DIAGNOSIS UNIT

5.



# MARQUÉS DEL TURIA EARLY DIAGNOSIS UNIT II

## EARLY DIAGNOSIS OF BREAST CANCER

### ACTIVITY INDICATORS

	2022	2021	Dif.	% Desv.
Women visited	15.902	16.379	-477	-3%
Cancers detected	190	117	73	62%


## EARLY DIAGNOSIS OF GYNAECOLOGICAL CANCER

### ACTIVITY INDICATORS

	2022	2021	Dif.	% Desv.
Women visited	4.065	4.218	-153	-4%
Women with pathologies	488	512	-24	-5%
Cancers detected	18	5	13	260%

## BREAST AND GYNAECOLOGICAL PATHOLOGY

### MALIGNANT PATHOLOGY



# I-ELCAP EARLY DETECTION UNIT

## DIAGNOSIS OF ASYMPTOMATIC LUNG CANCER

ACTIVITY	<b>Cumulative since the start of activity in June 2008 to December 2022</b>
Number of patients included	9.112
Number of reviews	47.373
Number of CT scans	54.867
Number of lung cancers detected	237
Other cancers detected	559

## EARLY DIAGNOSIS OF PROSTATE CANCER (OPPORTUNISTIC SCREENING)

ACTIVITY	<b>Activity from July 2010 to December 2022</b>
Number of patients included	10.623
Number of reviews	30.698
Number of cancers detected	365





**FUNDACIÓN**  
INSTITUTO VALENCIANO  
DE ONCOLOGÍA